The members of the Roivant Discovery scientific advisory board (SAB) are world-leading experts in quantum physics, computational drug development, parallel computing, biology and chemistry. Our SAB also includes clinicians whose insights into the needs of patients help guide the development of a new scientific paradigm and delivery of novel medicines for patients in need.
Timothy P. Heffernan, Ph.D.
Head of Oncology Research, Division of Therapeutics Discovery & Development; Executive Director, Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, The University of Texas MD Anderson Cancer Center, Houston.
Sun Hur, Ph.D.
Oscar M. Schloss Professor, Department of Biological Chemistry and Molecular Pharmacology, Department of Pediatrics, Harvard Medical School
Pasi A. Jänne, M.D., Ph.D.
Thoracic medical oncologist at the Dana-Farber Cancer Institute; Professor at Harvard Medical School; Director of the Lowe Center for Thoracic Oncology; Director of the Belfer Center for Applied Cancer Science